HanchorBio Invited to Participate in the 19th QIC CEO Week
Company to Meet with International Institutional Investors in Singapore to Share Corporate Progress and Strategic Priorities
[Taipei, Shanghai, and San Francisco, April 13, 2026] — HanchorBio, a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it has been invited to participate in the 19th QIC CEO Week hosted by Quantum International Corp (QIC). During the event, the Company will engage in a series of one-on-one and group meetings with international institutional investors to discuss its corporate progress, R&D advancement, and business strategy.
Through these meetings, HanchorBio seeks to further strengthen its engagement with the international capital markets and expand potential partnership opportunities.
The 19th QIC CEO Week is jointly organized by QIC, the Biomedical Technology and Device Research Laboratories of ITRI (ITRI BDL), and AAMA Taipei. This meeting will take place from April 14 to April 16, 2026 at The Fullerton Hotel, Singapore. As one of the region’s notable investor engagement platforms, the forum is expected to bring together approximately 200 representatives from international venture capital firms, family offices, strategic investors, Singapore’s major financial institutions, and leading institutional investors. According to the organizers, participating international institutional investors represent aggregate assets under management of more than US$20 trillion. The forum is expected to provide an important platform for deeper dialogue on industry trends and corporate strategy, while also offering participating Taiwanese companies an opportunity to connect with international investors, demonstrate their differentiated technological strengths, and further optimize shareholder structure.
HanchorBio will be represented by Dr. Scott Liu, Founder, Chairman and Chief Executive Officer, and Alan Tseng, Chief Financial Officer. Through these meetings, the Company will continue its dialogue with institutional investors and further its engagement with the international capital markets while exploring potential collaboration opportunities.
HanchorBio will provide updates on its overall business operations, R&D strategy, product portfolio, and future development plans, with the aim of supporting a broader understanding of the Company’s long-term growth strategy and core strengths.
Group Meeting Schedule
April 15, 2026
- 2:00 pm – 3:00 pm UTC+8
April 16, 2026
- 9:00 am – 10:00 am UTC+8
- 10:10 am – 11:10 am UTC+8
Additional one-on-one meetings will also be held during the event.
HanchorBio remains focused on the development of innovative biologic therapeutics and continues to advance its core technology platforms and product pipeline. By participating in this international investor event, the Company seeks to further strengthen its visibility within the global investment community and support its long-term growth and international development efforts.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.